ATYR (aTyr Pharma) ROE % Adjusted to Book Value: -52.14% (As of Mar. 2026)


ATYR aTyr Pharma Inc ATYR
14 GF Score
Price $0.56
GF Value $0.46
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is aTyr Pharma ROE % Adjusted to Book Value?

aTyr Pharma ATYR +0.41% 14 ROE % Adjusted to Book Value is -52.14% as of Mar. 2026. GuruFocus rates ATYR with a GF Score™ of 14/100 and a GF Value™ of $0.46 (Modestly Overvalued). The stock has 4 warning signs investors should review.

aTyr Pharma's ROE % for the quarter that ended in Mar. 2026 was -68.83%. aTyr Pharma's PB Ratio for the quarter that ended in Mar. 2026 was 1.32. aTyr Pharma's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was -52.14%.

aTyr Pharma ROE % Adjusted to Book Value Related Terms

aTyr Pharma ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for aTyr Pharma's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

aTyr Pharma ROE % Adjusted to Book Value Chart

aTyr Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only -25.22 -55.73 -63.43 -18.32 -94.57

aTyr Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -22.92 -16.57 -150.91 -66.33 -52.14

ATYR vs HYPD, GOSS, TIL: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, aTyr Pharma's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

aTyr Pharma ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, aTyr Pharma's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where aTyr Pharma's ROE % Adjusted to Book Value falls into.


ATYR
14GF Score
aTyr Pharma Inc ATYR
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

aTyr Pharma ROE % Adjusted to Book Value Calculation

aTyr Pharma's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-107.81% / 1.14
=-94.57%

aTyr Pharma's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-68.83% / 1.32
=-52.14%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -52.14% mean?
aTyr Pharma (ATYR) has a ROE % Adjusted to Book Value of -52.14% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on aTyr Pharma and its competitors.
Is aTyr Pharma's ROE % Adjusted to Book Value too high?
aTyr Pharma's current ROE % Adjusted to Book Value is -52.14%. Overall, aTyr Pharma has a GF Score™ of 14/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does aTyr Pharma's ROE % Adjusted to Book Value compare to HYPD and GOSS?
aTyr Pharma's ROE % Adjusted to Book Value of -52.14% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on aTyr Pharma and its competitors. aTyr Pharma's current ROE % Adjusted to Book Value is -52.14%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is aTyr Pharma stock overvalued right now?
Based on GuruFocus' analysis, aTyr Pharma (ATYR) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.46, compared to a current price of $0.56 — trading 22.2% above its estimated fair value. The current ROE % Adjusted to Book Value is -52.14%. aTyr Pharma's overall GF Score™ is 14/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For aTyr Pharma (ATYR), the current ROE % Adjusted to Book Value is -52.14% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is aTyr Pharma (ATYR) Overvalued in 2026?

Based on GuruFocus' analysis, aTyr Pharma stock appears to be overvalued. The current stock price of $0.56 is trading 22.2% above its estimated GF Value™ of $0.46. GuruFocus considers aTyr Pharma to be Modestly Overvalued.

Key valuation signals for ATYR:

  • ROE % Adjusted to Book Value: -52.14%
  • GF Value™: $0.46 vs. price of $0.56 (22.2% above fair value)
  • GF Score™: 14/100 with 4 warning signs

No single metric tells the full story. See the ATYR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

aTyr Pharma Business Description

Other Exchanges 471A:Germany
Address 10240 Sorrento Valley Road, Suite 300, San Diego, CA, USA, 92121
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).
14GF Score

Get the complete analysis for ATYR

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.56
Price
$0.46
GF Value